Group 1: Investor Relations Activity - The investor relations activity involved a meeting with analysts from Morgan Fund Management, Guolian Minsheng Securities, and Shenzhen Yide Global Fund Management on December 8, 2025 [1] - The meeting was held in the company conference room and included discussions on the company's new drug inclusion in the national medical insurance directory [1] Group 2: New Drug Inclusion - The innovative drug, Olanavir Tablets (brand name: Anruiwei®), was included in the National Medical Insurance Directory on December 7, 2025, following negotiations with the National Healthcare Security Administration [1][3] - Other core products such as Liraglutide Tablets and various capsules were also included in this directory, enhancing their market accessibility [1] Group 3: Drug Characteristics - Olanavir Tablets are the world's first oral drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for adult patients with uncomplicated influenza [3][4] - The drug demonstrates rapid symptom relief, strong antiviral effects, and low resistance rates, with positive results from clinical trials [4][5] Group 4: Sales and Marketing Strategy - The company plans to enhance marketing through three dimensions: building an academic ecosystem, upgrading data services, and implementing key project practices [8] - The inclusion of Olanavir Tablets in the National Medical Insurance Directory is expected to positively impact market promotion and long-term business development [8] Group 5: Pediatric Development Plans - The company is developing Olanavir Granules for children and adolescents, with ongoing Phase III clinical trials for both adolescents (ages 12-17) and children (ages 2-11) [9][11] - The trials aim to establish a comprehensive treatment matrix for influenza across all age groups [11] Group 6: Other Drug Developments - RAY1225 injection, an innovative dual-agonist drug for type 2 diabetes and obesity, has shown positive results in Phase II clinical trials and is progressing to Phase III trials [12][13] - ZSP1601 tablets, targeting metabolic dysfunction-related fatty liver disease, have completed early clinical trials with promising results and are moving into Phase IIb trials [15][16] Group 7: Research and Development Pipeline - The company is focusing on innovative drug development in respiratory and metabolic diseases, with projects targeting unmet clinical needs [16][18] - Ongoing research includes a new drug for respiratory syncytial virus (RSV) and various GLP-1 receptor agonists, with clinical candidates identified and preclinical studies underway [16][18]

问 3：请介绍公司未来除了将在手能源指标资产化项目化， 是否还有对外并购规划。 证券代码：002480 证券简称：新筑股份 成都市新筑路桥机械股份有限公司 投资者关系活动记录表 编号：2025-007 投 资 者关 系 活 动类别 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 活动参与人员 公司参与人员：董事会秘书陈思遥、首席合规官贾珺； 四川蜀道清洁能源集团有限公司：总工程师孙周； 参与机构：国新控股（四川）有限公司、国新盛康私募基金管 理（北京）有限公司 时间 2025 年 12 月 4 日（星期四）下午 3:00-5:00 地点 蜀道清洁能源集团 240 会议室 形式 现场交流 交 流 内容 及 具 体问答记录 一、基本情况介绍 成都市新筑路桥机械股份有限公司（以下简称"新筑股份 或公司"）副总经理、董事会秘书陈思遥简要介绍了公司历史 沿革、产业现状和本次重组背景，同时介绍了控股股东蜀道集 团三大主业板块（含清洁能源板块）、发展规划和产业协同。 二、问答环节 问 1：新筑股份本次重大资产重组完成后，对公司营收 ...

Group 1: Company Overview and Strategy - Hunan Jiutian Pharmaceutical Co., Ltd. is focusing on expanding its market presence through a multi-channel strategy and brand enhancement initiatives, including the launch of the "Jiutian Zhen Tong Xian Sheng" branding campaign on December 6, 2025 [2][3] - The company aims to strengthen its product pipeline by increasing R&D investments and introducing new products, while also leveraging its integrated supply chain to control costs and ensure product quality [3][4] Group 2: Product Specifics and Market Response - The company’s key product, Loxoprofen Sodium Gel Patch, has been selected in the 11th round of national drug centralized procurement at prices of ¥17.88 for 4 patches, ¥26.82 for 6 patches, and ¥35.76 for 8 patches, with a total planned selection of approximately 30.12 million patches [5] - Following the price reduction from centralized procurement, the company anticipates a potential increase in sales volume for Loxoprofen Sodium Gel Patch, contingent on market conditions post-implementation [5] Group 3: Mergers and Acquisitions - The company has acquired a 67% stake in Hunan Nona Pharmaceutical Technology Co., Ltd., which includes 67 drug licenses, enhancing its product offerings and market stability [3][4] - This acquisition is expected to fill potential sales gaps from the centralized procurement of Loxoprofen Sodium Gel Patch and diversify the product range with unique offerings like the Daiwen Moxibustion Patch [3] Group 4: Innovation and R&D Focus - The company is transitioning towards innovative drug development, establishing multiple R&D centers and focusing on various drug forms and cooperative models to expedite the development of new drugs [4][6] - Current R&D efforts are concentrated on oncology and chronic disease treatments, utilizing small molecules, peptides, and other advanced drug forms to build a robust pipeline [4][6] Group 5: Future Product Development - The JIJ02 gel is expected to complete Phase I clinical trials in the first half of 2026, with plans to initiate Phase II trials thereafter [7] - The company is optimistic about the market prospects for Ketoprofen Gel, which was approved in 2023 and included in the national medical insurance directory, and is implementing new sales strategies to enhance market penetration [7]

Group 1: Company Strategy and Innovation - The company emphasizes technological innovation as the foundation for its growth and industry leadership, addressing consumer pain points with solutions like the "blade battery" for safety and "DM-i super hybrid" for economic efficiency [2] - The R&D team, consisting of 120,000 members, is focused on developing advanced technologies to lead the industry in the coming years [2] - The company is committed to enhancing its design and marketing efforts to improve brand perception and consumer engagement [2] Group 2: Market Competition and Adaptation - The company acknowledges the intense market competition and is actively learning from successful practices of new entrants in the electric vehicle sector [2] - It plans to launch impressive technologies across its main and high-end brands, aiming to strengthen its market position and enhance global brand reputation [2] Group 3: Technology Communication and Marketing - The company has introduced technologies like "Heavenly Eye" and "Megawatt Flash Charge" to solidify its technological moat and intends to play a leading role in the industry [4] - The focus is on long-term growth through technology rather than aggressive short-term marketing tactics, ensuring sustainable market presence [4] Group 4: Artificial Intelligence and User Engagement - The company is heavily investing in artificial intelligence across various aspects, recognizing its transformative potential in the automotive industry [4] - With approximately 15 million electric vehicle users, the company prioritizes user feedback to guide its R&D efforts and enhance consumer experience [4] Group 5: Investor Relations - As of the end of Q3, the company has 640,000 shareholders and aims to maintain transparent communication while being cautious about revealing strategic plans in a competitive environment [4] - The company expresses gratitude towards its shareholders and is committed to delivering sustainable and innovative products for long-term benefits [5]

Company Overview - Yinchuan Weili Transmission Technology Co., Ltd. has a core production base located in Yinchuan, with all production capacity deployed there. The company focuses on precision reducers, wind power gearboxes, and electric drive-related capacities [1][2]. Industry Barriers - The wind power gearbox industry has high entry barriers, including: - **Technical Barriers**: Complex design requirements and high precision in processing and assembly, necessitating rigorous testing [1][2]. - **Financial Barriers**: Capital-intensive nature requiring significant investment in equipment and R&D [1][2]. - **Customer and Certification Barriers**: Strict supplier admission criteria and lengthy validation periods of 2-3 years [1][2]. - **Brand and Talent Barriers**: New brands struggle to gain trust, and the industry requires multidisciplinary talent [1][2]. Production Capacity - The first phase of the wind power gearbox smart factory is expected to achieve an annual production capacity of 2,000 units, with plans to increase to 4,000 units after the second phase [2][3]. Project Progress - The smart factory project is progressing steadily, with core production equipment deployed and ongoing adjustments to ensure operational stability. The company is actively recruiting and training staff for key positions [3][4]. Capacity Ramp-Up - The wind power gearbox smart factory is currently in the initial ramp-up phase, facing challenges such as: - Need for improved operational proficiency among the production team [3]. - Continuous optimization of production line processes [3]. - Ongoing equipment debugging and performance calibration [3]. Profitability Expectations - The smart factory is expected to significantly enhance the gross margin of the wind power gearbox business due to increased product value and cost reductions from economies of scale. The gross margin is anticipated to exceed that of conventional wind power gearbox products [4].

证券代码：002063 证券简称：远光软件 3.大数据业务未来的发展怎么看？ 公司不断推进大数据业务深化，当前聚焦数据治理、数 据场景服务、工具提供及智能场景，未来潜力在于激活客户 数据要素价值。电网数据真实、全面，能反映经济运行情况， 可用于多种场景。公司正积极探索与客户更多的合作模式， 未来将数据作为生产要素赋能更多领域，构建新增长极。 4.公司是否设有投资部，会并购与业务相关的标的吗？ 公司设有产业投资部，除了对子公司进行投后管理，提 供资源支持及业务赋能，负责低质无效资产的清理与处置， 如有合适标的，公司不排除通过并购重组方式扩大营收。 5.公司是否会考虑通过回购股份或分红等方式提升市 值？ 公司会综合考虑多种因素来决定是否采取回购股份、分 红、增持、股权激励或投资并购等措施提升市值。具体决策 将取决于公司资金的使用安排、股价表现以及回购用途等， 目前对各类提升市值的方式均持开放态度，但具体实施时点 需视实际情况评估确定。 远光软件股份有限公司 投资者关系活动记录表 编号： 20250024 投资者关系活动 类别 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 ...

Group 1: Market Structure and Competition - The domestic engineered wood machinery industry has a high concentration with few companies dominating the market, including Dieffenbacher, Siempelkamp, and Yalian Machinery [2][3] - High entry barriers exist due to the complexity of production processes and the need for integrated technology across multiple fields [3] - The core competitive advantages of Yalian Machinery include advanced technology, stable quality, strong brand recognition, and a skilled service team [3] Group 2: Capital Expenditure Outlook - Recent years have seen a push for capacity upgrades in the downstream engineered wood industry, leading to increased demand for advanced equipment [3][4] - The current supply-demand balance in the fiberboard industry is stable, while the particleboard sector is experiencing overheating in investment [4] - The overall profitability of the downstream industry is declining due to market pressures, leading to a decrease in new production line projects [4] Group 3: Order Fulfillment and Risks - The execution of engineered wood production line projects is complex and subject to various uncertainties, making timely delivery challenging [4] - Yalian Machinery currently has a sufficient order backlog, with most projects progressing as planned, and no significant risks of order cancellations [4] Group 4: International Expansion Strategy - Yalian Machinery's overseas business strategy focuses on regions with high demand for engineered wood, such as Southeast Asia, Eastern Europe, and Africa [5] - The company employs a direct sales model with customized pricing based on client needs, maintaining a consistent business model across domestic and international markets [5] - The overseas market presents significant growth opportunities due to rising demand and the need for improved equipment standards [5] Group 5: Profit Margins and Market Dynamics - The gross margin of Yalian Machinery's products is influenced by sales prices, procurement costs, and the scope of supply, with overseas projects typically having a broader scope [5] - While expanding the supply scope may dilute overall gross margins, it enhances total project profits and customer satisfaction through comprehensive solutions [5]

Group 1: Company Position and Market Outlook - Yingtai Co. ranks among the top five in the domestic laptop battery sector, primarily focusing on soft-pack batteries for laptops and tablets [2][3] - Yingtai's order visibility is generally around 8 weeks, with projected revenue for 2026 estimated at approximately ¥2 billion (excluding Youteli) and ¥900 million to ¥1 billion for Youteli [2][3] Group 2: Production Capacity and Expansion - Youteli's current soft-pack production line capacity is between 90,000 to 100,000 units, with plans to expand to 130,000 units after technical upgrades next year, and potential to reach 150,000 to 160,000 units with new factory construction [3] - Yingtai's Anhui factory has the potential to further expand Youteli's production capacity [3] Group 3: Product Applications and Collaborations - Youteli's products are primarily used in consumer electronics, including laptops, tablets, wearable devices, as well as in cleaning robots, drones, and medical equipment [3] - Yingtai is in discussions with a listed company for collaboration on magnesium-aluminum alloy structural components for humanoid robots, with a confidentiality agreement already signed [3] Group 4: Financial Strategies and Cost Management - Yingtai aims to minimize losses in the photovoltaic sector by fully utilizing existing production lines [3] - The company plans to establish its own anodizing workshop to reduce costs by 40%-50% in the anodizing process, which currently incurs high rental and utility expenses [3] Group 5: Strategic Acquisitions - The acquisition of Foshan Zhiqiang by Yingtai is seen as a low-cost entry into the North American supply chain for a certain brand, with ongoing negotiations for deeper collaboration [3]

Group 1: Company Performance and Challenges - The company's Q3 performance experienced a year-on-year decline due to project delays affecting revenue recognition, with varying product supply structures impacting gross margins [2][3] - The company aims to enhance its core competitiveness by actively participating in bidding for ventilation equipment projects and increasing R&D efforts [2][3] Group 2: Future Business Development - The strategic plan focuses on the ventilation and air treatment industry, accelerating new product development and expanding production capacity while maintaining a leading position in niche markets [3] - The company has established an overseas marketing department to expand into Southeast Asia and other international markets, following a dual strategy of "sailing out" and "self-sailing" [3] Group 3: Product Applications and Innovations - Ventilation equipment is crucial for safety and comfort, with potential applications in controlled nuclear fusion projects, depending on specific project requirements [4] - The 3D printing service is progressing well, offering customized solutions for various materials and industries, although it is not expected to significantly impact the company's current financial performance [6][7] Group 4: Incentives and Financing - Currently, there are no plans for equity incentives; the company will consider such plans based on strategic needs and market conditions in the future [5] - As of now, there is no financing requirement for the 3D printing business, but the company may explore refinancing options to expand operations as market demand evolves [6][7]

Group 1: Company Structure and Production - The company employs a vertically integrated production system, allowing for internal collaboration in dyeing and printing, which shortens production cycles and aligns with the fast-response trend in the industry [2] - The production capacity is currently at full load, with ongoing local expansions and efficiency improvements in existing equipment [3] Group 2: Financial Performance and Profitability - The company's self-use to external sales ratio for fabric products is approximately 1:1 in terms of value, with a higher volume of external sales [3] - The lower profit margins compared to peers like Shenzhou International are attributed to a smaller production scale, high R&D expenses, and increased demands for complex R&D from key clients [3] - The gross margin fluctuations are influenced by raw material costs (approximately 70% of costs), strong bargaining power of major clients, labor costs in Shanghai, and temporary increases in production costs due to smart equipment layout [4] Group 3: Market Strategy and Customer Base - The current customer base consists of approximately 60% international clients and 40% domestic clients, with plans to enhance market presence through technological innovation and sales channel expansion [3] - The company is open to collaborations with domestic brands for joint promotional activities to increase brand influence [3] Group 4: Raw Material and Cost Management - The company primarily uses wool as a raw material, with specific proportions not disclosed [4] - Wool price increases are expected to have a limited impact on gross margins due to long-term pricing agreements with suppliers, which provide time to adapt to market changes [4] Group 5: Investment and Future Plans - The company has added production capacity in Vietnam in 2025 and plans to maintain a focus on core business while considering future expansions based on cash flow and market conditions [3] - Investment returns from the Masood joint venture have been volatile due to a significant procurement incident in 2024, but improvements in management are expected to stabilize performance [4]